| Metric | Value (₹ Cr) | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue | 610.45 | 13.9% | 45.9% |
| Total Income | 610.92 | 13.9% | 46.0% |
| Expenditure | 520.77 | 17.7% | 37.4% |
| PBT | 88.11 | 5.9% | 124.0% |
| Net Profit | 71.47 | 6.1% | 156.0% |
| OPM | 21.81% | 3.59pp | 3.95pp |
| NPM | 11.70% | 2.50pp | 5.03pp |
| EPS | 7.88 | 6.2% | 155.8% |
Can Aarti sustain momentum as capacity ramps and stamp duty clouds clarity?
Q1's 38% revenue growth and 65% PAT surge set a high bar. On-plan Q2 would mean continued API strength and early traction from the Tarapur Unit 5 expansion—offset by a ₹59.5 Cr stamp duty order that management is contesting.
The Setup
Aarti Pharmalabs reported a blowout Q1 FY27 on August 7: consolidated revenue jumped 38.7% YoY to ₹535.80 Cr (against a restated FY26 Q1 base of ₹386.19 Cr), while PAT surged 65.4% YoY to ₹76.14 Cr, expanding margins to 25.4% OPM. The company attributed growth to strong API demand and improved capacity utilization from its CDMO (contract manufacturing) business. Management expects this trajectory to continue through H2 FY27 if the API upcycle and CDMO orders sustain—and the newly commissioned Tarapur Unit 5 manufacturing block (3600 TPA for Xanthine derivatives, announced June 30) reaches commercial run rate by Q3 or Q4.
Q2 will test whether that momentum holds. The Street consensus is more measured: analysts project 15–20% FY27 PAT growth (full-year), implying Q2 expectations closer to 20–30% rather than Q1's exceptional 65%. A strong quarter would mean revenue in the ₹500–540 Cr range with OPM sustained near 25%, signaling API demand remains resilient and CDMO margins are sticky. A weak quarter would be revenue below ₹480 Cr or OPM compression below 23%, suggesting demand moderation or CDMO pricing pressure.
~₹500–540 Cr
On-plan would track Q1's 38%+ YoY growth trajectory if API/CDMO momentum persists
~23–25.5%
Sustained if product mix stays favorable and capacity leverage continues from Tarapur ramp
~₹55–70 Cr (est.)
FY27 full-year consensus targets 15–20% growth; Q2 would need ~25%+ YoY to hit that
Monitor
Q2 FY26 saw ₹7.4 Cr forex loss; watch if INR volatility recurs
On Track for FY27?
Aarti Pharmalabs is on the growth vector for FY27. Q1's 38.7% revenue growth and 25.4% OPM far exceed the Street's base case of 15–20% PAT growth, suggesting upside if momentum continues. However, the stamp duty order (₹59.5 Cr levied September 2, contested) creates uncertainty: if the writ petition at Gujarat High Court fails, the charge would materially dent FY27 earnings. Management has flagged the challenge, but a loss on the order could pull FY27 PAT growth back to low-single digits, breaking the consensus view. The new Tarapur capacity adds optionality: if CDMO demand sustains and utilization climbs in H2, it could offset any margin normalization from API price moderation.
What the Street Says
Since Last Quarter
Operational: Tarapur Unit 5 manufacturing block inaugurated (June 30) with 3600 TPA Xanthine capacity, part of broader capex to unlock API/CDMO scaling. This is positive for H2 utilization and medium-term growth, but ramp risk exists.
Regulatory & Legal: Stamp duty order for ₹59.5 Cr issued by the Office of Superintendent of Stamps, Gandhinagar (Aug 29, notified Sep 2). Aarti filed a Writ Petition at Gujarat High Court (Sep 30) challenging the order. No ruling yet; watch Q2 commentary for management's confidence in the outcome. This is the single largest tail risk to FY27 earnings.
Corporate Governance: 7th AGM held Sep 22. Director Rajendra Gogri (Non-Executive, Non-Independent) stepped down. Nomination & Remuneration Committee reconstituted effective Oct 1. Board-level changes are routine, but flag any management commentary on strategy or capex.
Capital Actions: Final dividend of 40% (₹2.00 per share) for FY26 approved; record date Sep 15. Trading window for Q2 results closed Sep 28 (routine for insider trading compliance).
Ownership: Promoter shareholding stable near 42.9%; FII 8.17% in Q1 (slight dip from Q4's 8.39%); DII 7.22% (slight dip from Q4's 7.41%). No material pledging or insider buying/selling noted in recent bulk/block deals. Bulk activity in mid-Sep around ₹820–904, largely two-way flow (buying by UNIFI CAPITAL, QE SECURITIES, MICROCURVES; selling by JASMINE FAMILY TRUST, QE in Sep 18 cross).
What to Watch on Result Day (Oct 28)
1 · Revenue & margin beat?
Does Q2 deliver ₹500+ Cr revenue and sustain 24%+ OPM, or is there moderation? Watch management's tone on API pricing and CDMO pipeline for H2.
2 · Tarapur Unit 5 ramp trajectory
Any update on capacity utilization, customer pull, or expected contribution timing? Early signs of traction vs delays would set tone for FY27 guidance.
3 · Stamp duty order update
Has the Gujarat High Court writ petition progressed? Management confidence in overturning the ₹59.5 Cr order, or should investors model a potential loss? This alone could swing FY27 guidance.
4 · FY27 guidance / management commentary
Do they reaffirm the 15–20% FY27 PAT growth consensus, or revise higher (Q1 trajectory) or lower (stamp duty risk)? Watch for capex updates and any commentary on API/CDMO market conditions.
5 · Forex & other P&L items
Q2 FY26 saw a ₹7.4 Cr forex loss; is that a one-off or a structural headwind? Look for hedging disclosure or currency sensitivity notes.
Aarti Pharmalabs enters Q2 results on a strong growth footing—Q1's 38% revenue and 65% profit surge positioned the stock as a post-covid recovery play with operating leverage. But clarity is clouded by the contested ₹59.5 Cr stamp duty order and the execution risk on the new Tarapur capacity. Q2 will test whether management can hold margins and API momentum, or whether the easy comps and CDMO demand are normalizing. A beat (₹510+ Cr revenue, 25%+ OPM, PAT beat consensus by 10%+) would justify the 12-month ₹920–970 target and refresh the bulls. A miss—especially on margins or if the stamp duty ruling goes against Aarti—risks a sharp re-rate toward the low ₹750s.
Record growth masks rising execution risk — Xanthine guidance cut signals caution
Aarti delivered record revenue growth of 45.9% YoY and PAT nearly tripled, but management cut Xanthine FY27 guidance by ₹120–₹220 Crore and reported weak cash conversion. The call reveals a company executing strategically but uncertain on near-term pricing power.
₹610.5 Cr
+45.9% YoY, +13.9% QoQ
₹71.5 Cr
+156% YoY, -6.1% QoQ
22.2%
+450bp YoY; at guidance floor
₹30 Cr
only 22% of ₹136 Cr EBITDA
The headline numbers are impressive: revenue nearly doubled YoY, PAT surged 156%. But the quarter reveals a company managing growth against near-term headwinds. While EBITDA margins held at 22.2% (within guidance), they're at the floor of the 22–25% range, signalling pressure. More tellingly, operating cash flow lagged earnings sharply — just ₹30 Crore against ₹136 Crore EBITDA — and the company cut Xanthine guidance by roughly ₹120 Crore from Q1's run-rate, citing price normalization. That cut is the real story of the quarter.
The Xanthine reckoning
In Q1, management's run-rate implied Xanthine revenue of ₹1,220 Crore annualized. On this call, that was downgraded to ₹900–₹1,100 Crore for full FY27 — the midpoint (₹1,000 Cr) is ₹220 Cr below the prior trajectory, or roughly 18% lower. The stated reason: price normalization as raw material costs stabilise. Xanthine spot prices had risen 10–15% YoY, supported by crude and China supply tightness; as those pressures ease, the company faces customer pushback on previously locked-in pricing. Management deflected hard when analysts pressed on near-term pricing realization. When asked how much pass-through Aarti would see in Q3–Q4, the MD held firm that 'it's normal' and Q3–Q4 should recover — but offered no quantified guidance on per-unit realization or Q2's actual pricing decline. That evasion suggests internal uncertainty on the trajectory.
Q2 revenue ₹613 Cr, YoY +47%
₹610.5 Cr delivered, YoY +45.9% (0.4% variance)
Supported (close guidance)
Q2 PAT ₹66 Cr, YoY +175%
₹71.5 Cr delivered (8.3% above guidance), YoY +156%
Understated in remarks; actual PAT beat
CDMO near-doubling Q1 to Q2
CDMO 13% of Q2 revenue (~₹79 Cr); Q1 absolute not provided; unverified
Unverified in absolute terms
Xanthine flat/slightly down QoQ; 5% volume spillover
QoQ revenue +13.9% but PAT -6.1% (margin/mix shift); Xanthine FY27 guidance cut
Contradicted — guidance revision signals material weakness ahead
What shifted on guidance
Xanthine FY27 revenue: Cut from ₹1,220 Cr implied run-rate (Q1) to ₹900–₹1,100 Cr. Material downgrade, attributed to price normalization. H2 Xanthine likely ~₹305–350 Cr (flat to modest growth vs. H1 ~₹305 Cr). CDMO 40–50% growth: Maintained. 59 projects (39 commercial, 20 development); targeting ₹1,000 Cr by FY29–30. Two major molecules launching next year; no upgrade or cut. EBITDA margin 22–25% FY27: Reaffirmed. Q2 at 22.2% (lower end); management expects raw material pass-through to recover margins in Q3–Q4. API long-term ₹1,000 Cr aspiration: Unchanged, but near-term growth hedged. When challenged on FY27–FY28 API growth, management repeatedly deferred to 'three-year guidance' rather than quantifying near-term expansion. Current run-rate ~₹180 Cr. Capex ₹350–400 Cr FY27: Maintained (₹150 Cr H1, ₹250+ Cr H2). No reduction despite weak cash flow.
Cash flow and debt — the real constraint
Despite record earnings, operating cash flow remained weak at ₹30 Crore in Q2 — only 22% of EBITDA. The culprit: working capital. Inventories and receivables surged with 45%+ revenue growth, pushing the cash conversion cycle to 150–167 days. At that cycle, ₹610 Cr quarterly revenue requires roughly ₹250+ Crore in working capital financing. Capex demands are ferocious: ₹350–400 Cr for the full year (33% of revenue). Management already carries ₹650 Crore in short-term borrowing and acknowledged needing 'more debt' for H2 capex. Pro-forma debt/EBITDA is climbing toward 2.5x+. Management claims capex depreciation and CDMO margin uplift will drive FCF recovery from H2 onwards — but that's a 2–3 quarter story, not immediate.
The bull-bear debate
Record revenue ₹610.5 Cr; +45.9% YoY growth sustained
CDMO 40–50% growth maintained; 59 projects, 23 customers diversified
EBITDA margin 22.2% within guidance; raw material pass-through expected
Atali steroid API capex on track; Xanthine capacity ramp underway
Xanthine FY27 guidance cut ₹120–₹220 Cr from run-rate; price normalization risk
Operating cash flow ₹30 Cr (22% of EBITDA); working capital cycle 150–167 days
Capex intensity 33% of revenue; debt ₹650 Cr outstanding; ₹250+ Cr H2 needs
API declining as % of mix (43% FY25 → 30% FY27); no near-term growth guidance
Management tone shifted to defensive on API, peptide, near-term guidance
CDMO execution risk on 20 development-stage projects; growth contingent on launches
Ranked risks
Xanthine price normalization and margin compression
HighXanthine is 50% of Q2 revenue. Guidance cut signals pricing power erosion. If spot prices fall sharply or pharma customers demand further concessions, FY27–FY28 revenue and margins could disappoint further.
CDMO execution on 20 development-stage projects
High40–50% CDMO growth target depends on timely customer approvals and commercial scaling. 20 projects still in development carry delay and cancellation risk. Major slips would derail growth target.
Working capital deterioration and cash flow stress
HighCFO ₹30 Cr on ₹136 Cr EBITDA (22%) is dangerously low. Inventory and receivables rising faster than sales. If growth slows or collections stretch, capex and debt servicing could be squeezed.
Debt trajectory and refinancing risk
MediumShort-term debt ₹650 Cr; H2 capex ₹250+ Cr likely means total debt >₹900 Cr by year-end. Debt/EBITDA ~2.5x+. If capex doesn't generate FCF by FY28, refinancing becomes challenging.
API segment mix shift and growth slowdown
MediumAPI declining (43% FY25 → 30% FY27) with no visibility on near-term acceleration. Long-term ₹1,000 Cr aspiration lacks a clear path. If CDMO growth slows, API stagnation leaves no offset.
How the street is positioned
The stock is trading at ₹919.95, up 57% from its 52-week low of ₹585 but down 7.93% from its all-time high of ₹999.2. It sits above all key moving averages (SMA20 ₹878.32, SMA50 ₹872.55, SMA200 ₹749.44), but RSI at 56.4 is neutral. Volume is increasing, suggesting continued institutional interest. Ownership flows are mixed. FII ownership ticked down 0.22 percentage points QoQ to 8.17% (Q1 FY27), while DII trimmed 0.19pp to 7.22%. Promoter stake stable at 42.86%. The outflow suggests modest profit-taking by foreign investors, though the slide is measured. Bulk deal activity over six months reveals institutional conviction — buyers (Unifi Capital, Microcurves, QE Securities) accumulating in the ₹820–₹904 range in mid-September. Recent selling by the same institutions at ₹902–₹904 suggests they are locking in gains near highs. No promoter insider selling flagged — positive signal. The verdict on tape: The stock has run hard off lows but is consolidating near highs. Institutional buyers are testing the upside but also trimming profits. The price action — rising volume but FII outflows — suggests the market is sceptical that guidance cuts and cash flow weakness are fully priced in. Sideways consolidation would be consistent with pending clarity on Q3 raw material pass-through and CDMO launches.
What to watch next
1 · Q3 EBITDA margin recovery and Xanthine realization
Management guided for raw material pass-through to recover margins toward 22–25% mid-range in Q3–Q4. If Q3 EBITDA margin stays at 22.2% or slips, it signals pass-through is slower or pricing decay sharper than guided. Track Xanthine per-unit realization; any further decline undermines FY27 guidance.
2 · CDMO molecule launches and customer wins
Management stated two major CDMO molecules launching next year (FY28). Commercialization delays, failed approvals, or customer losses would signal execution risk. Expect Q3–Q4 commentary on project progression; major delays would pressure 40–50% growth target.
3 · Atali ramp-up and capex completion
Atali Phase 1B trials underway; full commercialization ramping H2 FY28. Setbacks or delays would defer capex ROI and keep debt/EBITDA elevated. Track capex spend and completion timelines in Q3–Q4.
4 · Operating cash flow recovery and debt trajectory
Management claims FCF to improve from H2 onwards as capex depreciation kicks in and working capital normalizes. If Q3–Q4 CFO stays weak (<₹50 Cr per quarter), refinancing risk rises. Track debt/EBITDA; if it breaches 2.75x, refinancing becomes urgent.
Aarti Pharmalabs delivered record growth but no step-change this quarter. The company is executing a credible multi-year capex and CDMO transition strategy — Atali, Xanthine capacity, peptide lab, new modalities. But near-term visibility is clouded by Xanthine price normalization (guidance cut ₹120–₹220 Cr), weak cash flow (CFO ₹30 Cr on ₹136 Cr EBITDA), and rising debt (₹650 Cr outstanding, ₹250+ Cr H2 capex needs). Management's defensive tone when pressed on API and near-term guidance signals internal caution on short-term trajectory.
The single number to track: free cash flow and debt/EBITDA. If Q3–Q4 CFO recovers above ₹50 Cr per quarter and debt/EBITDA holds below 2.5x into FY28, the long-term story holds. If FCF remains anaemic and debt/EBITDA breaches 2.75x, refinancing and deleveraging risks become material. The bull-case CDMO growth and margin recovery hinge on execution; the bear-case on Xanthine weakness and working capital drag. Aarti is not a story to own on momentum — it's one to re-evaluate once Q3 cash flow and margin data arrive.
Record growth masks capex intensity, Xanthine guidance cut signals caution
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
Delivered higher PAT (₹71.5 Cr vs ₹66 Cr guided) and revenue beat (610.5 vs 613 stated), but downgraded Xanthine FY27 revenue by ₹120 Cr midpoint vs Q1 run-rate.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Aarti delivered strong H1 growth (45.9% revenue, 156% PAT) with maintained EBITDA margins (22.2%), but management cut Xanthine guidance from ₹1,220 run-rate to ₹900-₹1,100 Cr FY27, signaling price normalization risk. Heavy capex (₹350-400 Cr FY27) and rising debt (₹250+ Cr H2 needed) compress near-term FCF, while API segment declining as % of mix. Long-term CDMO growth (40-50%) and Xanthine capacity ramp are credible, but execution risks on 20 development-stage projects and uncertain near-term guidance.
₹610.5 Cr
Revenue · +45.9% YoY₹71.5 Cr
Reported PAT · +156% YoYCompressing
Margins · vs guidance: MixedDid the claims hold up?
Q2 revenue ₹613 Cr, YoY +47%
MET₹610.5 Cr delivered, YoY +45.9%; 0.4% variance and 1.1% YoY variance within rounding
Q2 PAT ₹66 Cr, YoY +175%
OVERSTATED₹71.5 Cr delivered (8.3% higher), YoY +156%; management understated actual PAT
EBITDA margin 22.2% in Q2, +450bp YoY
METMargins healthy vs 17.7% prior year; Q2 at lower end of 22-25% guidance range
Xanthine sales flat/slightly down QoQ due to shipment issues; 5% volume spillover
MISSQoQ revenue +13.9% but PAT -6.1%, indicating margin/mix shift; Xanthine guidance cut to ₹900-₹1,100 Cr FY27 vs ₹1,220 run-rate Q1
CDMO near-doubling Q1 to Q2 sales
UnverifiedCDMO stated as 13% of Q2 revenue = ~₹79 Cr; no Q1 CDMO absolute given; growth claim unverified
Earnings quality
What changed since the last call
Xanthine FY27 revenue guidance
CutQ1 implied run-rate ₹1,220 Cr → FY27 guided ₹900-₹1,100 Cr (₹1,000 Cr midpoint). Attributed to price normalization as raw material costs subside; -₹120 Cr midpoint cut is material (~12% downgrade).
CDMO growth target
MaintainedReaffirmed 40-50% growth FY27-FY28; 59 projects, 39 commercial, 20 development; two major molecules launching next year. No upgrade or cut from prior guidance.
EBITDA margin guidance
Maintained22-25% FY27 maintained from prior call; Q2 at 22.2% (lower end); raw material pass-through expected to improve Q3-Q4 margins back toward range.
API long-term aspiration
Maintained₹1,000 Cr long-term API target unchanged; near-term growth hedged (10-15% annually on API+intermediate); current ~₹180 Cr run-rate.
Capex guidance
Neutral₹350-400 Cr FY27 total (₹150 Cr H1, ₹250+ Cr H2); Atali and Xanthine capacity expansion continuing; no change from prior stated capex plans.
The Q&A
Analysts pressed hard on three fronts: (1) margin compression from raw materials — management deflected, claiming pass-through normal and Q3-Q4 will recover; (2) Xanthine pricing decline vs Q1 — management blamed temporary shipment issues and mix shift, avoided giving near-term realization guidance; (3) near-term growth acceleration — management dodged, repeatedly referencing 3-year guidance vs quarterly volatility. MD Rashesh Gogri held firm on CDMO 40-50% but showed caution on API and Xanthine, signaling uncertainty.
Xanthine pricing & utilization — Ahmed Madha, Unifi Capital
AnsweredAtali Phase 1 complete; Phase 1B trials underway, commercialization H2 FY28. Xanthine expansion two-phase; first phase finished, second ramping. Full capitalization by year-end.
Raw material pass-through & margins — Sudarshan Padmanabhan, Ashika
PartialCDMO sales nearly doubled Q1. Xanthine and allied chemistry normally pass costs on. Q3-Q4 should catch up on pass-through pricing.
Xanthine capacity & revenue potential — Ankit Gupta, Bamboo Capital
AnsweredIf prices remain high, ₹1,400-₹1,500 Cr at full capacity. Currently near 7,000 out of 9,600 units. Will gradually reach 90% over two years.
API near-term growth drivers — Dhwanil Desai, Turtle Capital
PartialAPI+intermediate currently ₹180 Cr run-rate. Growth largely volume-driven. CDMO growth also helping. De-bottlenecking of steroid block underway, Q2 onwards improved sales.
CDMO product mix & therapeutic areas — Kushal Goenka, Mangal Keshav
AnsweredProducts for antihypertensive, pain management, anti-cancer, CNS; varied range. Peptide lab set up by end FY27; commercial customer business expected FY28.
Xanthine pricing trends YoY — Ashish, Leo Capital
AnsweredPrices up 10-15% YoY average. Overall 15%-20% jump expected this year on volume. Utilization: 7,000 near-term, gradually 8,800-9,600 in two years.
Xanthine shipment delays & CDMO confidence — Aaryan Mehta, Shravas Capital
AnsweredShipment issue caused ~5% Q2 spillover. CDMO growth 40-50% maintained — confident on guidance. Third, fourth quarter should see higher CDMO sales.
Xanthine realization and debt trajectory — Arun, Unifi Capital
DodgedXanthine realization softened slightly due to allied chemistry mix. Overall allied products saw higher turnover. More debt needed beyond H1; financing arranged for capex.
API long-term guidance vs current trajectory — Rupesh Tatiya, Long Equity Partners
DodgedNot upgrading FY27 guidance; giving 3-year guidance only. Growth dependent on new product approvals. R&D investment increasing. This year looks promising.
CDMO revenue milestone & capacity allocation — Ankit Gupta, Bamboo Capital
AnsweredTarget ₹1,000 Cr CDMO revenue; 100 million molecules; whichever first. Depend on customer approvals. 59 projects, good potential. Fairly confident to achieve.
Peptide & oligonucleotide R&D spend and timeline — Piyush Bangar, Vijit Global
DodgedLab operational by end FY27. Too early to give numbers or guidance. Question next year better.
DMF filings and Onco drug upside — Tushar Raghatate, Omega Portfolio
Answered61 APIs; several patent expires expected next year to launch in partners' markets. Strong Onco portfolio. Peptides, oligonucleotides large molecules; developing modalities. Few modalities, linkers, ADC linkers; will be offered.
Xanthine spot vs pharma/beverage segment breakdown — Ameya Deosthali, Value Equity
DodgedDon't give that segment breakup currently.
Guidance
FY27 overall growth 15-18% conservatively (implied from prior guidance)
LowH1 delivered 45.9% growth; H2 would need to decelerate sharply for full-year 15-18%. Management suggests full-year will be 'higher' than this. Guidance outdated or very conservative.
Xanthine FY27 ₹900-₹1,100 Cr (₹1,000 Cr midpoint)
MediumDown from ₹1,220 Cr Q1 run-rate; attributed to price normalization as raw materials stabilize. Implies H2 Xanthine ~₹305-350 Cr (flat to modest growth).
CDMO ₹1,000 Cr (100 million molecules) by FY29-30 aspiration
MediumImplies ~₹280-300 Cr CDMO run-rate by FY29-30; 40-50% growth maintained for next 2 years. Dependent on customer approvals and project commercialization.
API long-term ₹1,000 Cr target (no near-term quantified)
LowCurrent ~₹180 Cr run-rate; 5-year+ horizon. Management declined to quantify FY27-FY28 API growth, hedging on approval timelines.
FY27 EBITDA margin 22-25%
MediumQ2 delivered 22.2% (within range, lower end). Raw material cost pass-through expected to aid Q3-Q4. Capex depreciation and CDMO growth (higher margin) should support margins.
OPM steady-to-improving (no explicit %)
LowCapex depreciation starting H2; operating leverage from higher sales expected to expand margins 100-150bp into FY28.
FY27 capex ₹350-400 Cr total
HighH1 ~₹150 Cr deployed; H2 ₹250+ Cr planned for Atali (steroid API) and Xanthine expansion. Management confirmed 'more debt needed' for H2 capex.
Atali capex front-loaded FY27-FY28; completion by FY27 ramp
HighPhase 1A complete; Phase 1B trials underway. Full utilization phased in H2 FY28 onwards.
Risks the call surfaced
Raw material pricing
HighXanthine prices up 10-15% YoY but normalized guidance (₹900-₹1,100 Cr) implies price pressure ahead. Crude and China export tariffs could impact cost structure. Pass-through to customers lagging by 1-2 quarters.
CDMO project execution
High59 CDMO projects, 39 commercial stage, 20 development; 40-50% growth target depends on timely customer approvals and successful scaling. Failed or delayed projects could derail revenue growth.
Working capital deterioration
HighInventories and receivables surging with 45%+ revenue growth; 150-167 day cash conversion cycle means ₹610 Cr revenue requires ~₹250 Cr+ working capital. Q2 CFO only ₹30 Cr (22% of EBITDA) signals stress.
Debt and leverage
MediumShort-term borrowing already ₹650 Cr; H2 capex needs ₹250+ Cr more debt. Total debt rising sharply; interest burden increasing with rates; refinancing risk if capex doesn't generate FCF quickly.
API segment mix shift
MediumAPI% of revenue declining (43% FY25 → 30% FY27); API long-term target ₹1,000 Cr has no near-term path. Mix shifting to lower-margin CDMO and intermediate products; growth driver lacks visibility.
Management
Score 6/10. Mixed clarity. Management provided detailed operational metrics (project counts, capacity numbers, segment splits) but repeatedly deflected quantified near-term guidance on API and peptide revenue. Acknowledged raw material pressure but hedged on near-term margin impact. Good track record on strategic capex (Atali on track, Xanthine expansion underway); delivered higher PAT than guided (71.5 vs 66 Cr). But Xanthine guidance cut by ₹120 Cr midpoint vs Q1 run-rate suggests forecast volatility or prior optimism.
1 · H2 FY27
Atali Phase 1B block ramp-up; Xanthine capacity expansion to 8,800+ units; peptide lab operational
2 · FY28
Peptide lab commercialization (not expected to contribute material revenue FY27); API new product launches (DMF filings, Onco products)
3 · FY28-FY29
CDMO 6 commercial molecules ramp; 20 development projects advancing; API aspires >10-15% growth if DMF products gain traction
Long-term CDMO growth (40-50%) and Xanthine capacity ramp are credible, but execution risks on 20 development-stage projects and uncertain near-term guidance.